SCTX
Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. (SCTX) has 7 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 29, 2026.
Insiders have net bought $71.3M over the trailing 6 months. The largest single insider purchase in this window was $36.1M by Director, 10% Owner Aghazadeh Behzad on Jul 24, 2026.
- Industry:Biotechnology
- CEO:Benjamin L. Oakes
- HQ:Alameda, CA, US
- IPO:2026-07-24
Insider Buying
$71.3M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
AH Bio Fund II, L.P.First filing | 10% Owner | Purchase | 333,333 | $5.0M | Jul 29 | SEC ↗ |
GORDON CARL LFirst filing | Director | Purchase | 1,000,000 | $15.0M | Jul 29 | SEC ↗ |
| Director | Purchase | 1,000,000 | $15.0M | Jul 29 | SEC ↗ | |
Aghazadeh BehzadFirst filing | See Remarks | Purchase | 2,383,333 | $36.1M | Jul 29 | SEC ↗ |
Aghazadeh BehzadFirst filing | See Remarks | Purchase | 7,905 | $144K | Jul 29 | SEC ↗ |
Lucas SvetlanaFirst filing | Chief Business Officer | Purchase | 3,000 | $45K | Jul 28 | SEC ↗ |
Parrot DavidFirst filing | Chief Financial Officer | Purchase | 1,333 | $20K | Jul 28 | SEC ↗ |
Related companies
Scribe Therapeutics, Inc. is in the Healthcare sector.